Protease-activated receptors in cancer: A systematic review

被引:42
作者
Han, Na [1 ,2 ]
Jin, Ketao [3 ,4 ]
He, Kuifeng [3 ]
Cao, Jiang [1 ,2 ,5 ]
Teng, Lisong [3 ]
机构
[1] Zhejiang Univ, Sir Run Run Shaw Inst Clin Med, Hangzhou 310016, Zhejiang, Peoples R China
[2] Key Lab Biotherapy Zhejiang Prov, Hangzhou 310016, Zhejiang, Peoples R China
[3] Zhejiang Univ, Dept Surg Oncol, Affiliated Hosp 1, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China
[4] Wenzhou Med Coll, Zhuji Hosp, Dept Surg, Zhuji 311800, Zhejiang, Peoples R China
[5] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Clin Res Ctr, Hangzhou 310003, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
angiogenesis; cancer; protease-activated receptors; tumorigenesis; MOLECULAR-WEIGHT HEPARIN; ENDOTHELIAL GROWTH-FACTOR; THROMBIN-INDUCED ANGIOGENESIS; PEPDUCIN-BASED INTERVENTION; HUMAN PLATELET ACTIVATION; TUMOR-SUPPRESSOR PROTEIN; TISSUE FACTOR; IN-VITRO; CELL-PROLIFERATION; ANTIANGIOGENIC AGENTS;
D O I
10.3892/ol.2011.291
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The traditional view of the role of proteases in tumor growth, progression and metastasis has significantly changed. Apart from their contribution to cancer progression, it is evident that a subclass of proteases, such as thrombin, serves as signal molecules controlling cell functions through the protease-activated receptors (PARs). Among the four types of PAR (PAR 1-4; cloned and named in order of their discovery), PAR1, PAR3 and PAR4 are activated by thrombin, unlike PAR2, which is activated by trypsin-like serine proteases. Thrombin has been proven to be a significant factor in both the behavior of cancer in its involvement in hemostasis and blood coagulation. Thrombin is a key supporter of various cellular effects relevant to tumor growth and metastasis, as well as a potent activator of angiogenesis, which is essential for the growth and development of all solid tumor types. This review presents an overview of the role of PAR-mediated thrombin in angiogenesis and cancer, focusing on the ability of PAR1- and PAR4-mediated thrombin to affect tumorigenesis and angiogenesis.
引用
收藏
页码:599 / 608
页数:10
相关论文
共 157 条
  • [61] Integrin affinity modulation
    Hughes, PE
    Pfaff, M
    [J]. TRENDS IN CELL BIOLOGY, 1998, 8 (09) : 359 - 364
  • [62] THROMBOSPONDIN EXERTS AN ANTIANGIOGENIC EFFECT ON CORD FORMATION BY ENDOTHELIAL-CELLS INVITRO
    IRUELAARISPE, ML
    BORNSTEIN, P
    SAGE, H
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (11) : 5026 - 5030
  • [63] Protease-activated receptor 3 is a second thrombin receptor in humans
    Ishihara, H
    Connolly, AJ
    Zeng, DW
    Kahn, ML
    Zheng, YW
    Timmons, C
    Tram, T
    Coughlin, SR
    [J]. NATURE, 1997, 386 (6624) : 502 - 506
  • [64] Angiogenesis is regulated by a novel mechanism:: pro- and antiangiogenic proteins are organized into separate platelet α granules and differentially released
    Italiano, Joseph E., Jr.
    Richardson, Jennifer L.
    Patel-Hett, Sunita
    Battinelli, Elisabeth
    Zaslavsky, Alexander
    Short, Sarah
    Ryeom, Sandra
    Folkman, Judah
    Klement, Giannoula L.
    [J]. BLOOD, 2008, 111 (03) : 1227 - 1233
  • [65] Jamieson GA, 1997, THROMB HAEMOSTASIS, V78, P242
  • [66] Protease-activated receptor (PAR)-l and PAR-2 participate in the cell growth of alveolar capillary endothelium in primary lung adenocarcinomas
    Jin, EJ
    Fujiwara, M
    Pan, X
    Ghazizadeh, M
    Arai, S
    Ohaki, Y
    Kajiwara, K
    Takemura, T
    Kawanami, O
    [J]. CANCER, 2003, 97 (03) : 703 - 713
  • [67] Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?
    Jin, Ketao
    Shen, Yanping
    He, Kuifeng
    Xu, Zhenzhen
    Li, Guangliang
    Teng, Lisong
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2010, 12 (08) : 526 - 532
  • [68] Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin
    Kahn, ML
    Nakanishi-Matsui, M
    Shapiro, MJ
    Ishihara, H
    Coughlin, SR
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (06) : 879 - 887
  • [69] A dual thrombin receptor system for platelet activation
    Kahn, ML
    Zheng, YW
    Huang, W
    Bigornia, V
    Zeng, DW
    Moff, S
    Farese, RV
    Tam, C
    Coughlin, SR
    [J]. NATURE, 1998, 394 (6694) : 690 - 694
  • [70] Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS)
    Kakkar, AK
    Levine, MN
    Kadziola, Z
    Lemoine, NR
    Low, V
    Patel, HK
    Rustin, G
    Thomas, M
    Quigley, M
    Williamson, RCN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (10) : 1944 - 1948